Concepedia

Johan Falkenius

JF

Statistics

Publications

7

Citations

190

H-Index

7

Active since

2012

Affiliations

Karolinska University Hospital(Current)

Karolinska Institutet

The Netherlands Cancer Institute

Heidelberg University

Merck KGaA, Darmstadt (Germany)

Johan Falkenius is an author at Karolinska University Hospital specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

2012–2023

7

Publications

7

A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors

Michael A. Samuels, Johan Falkenius, Voichita Bar‐Ad et al. · International Journal of Radiation Oncology*Biology*Physics · 2023 · 66 citations · Full text

, , +15

High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma

Johan Falkenius, Joakim Lundeberg, Hemming Johansson et al. · Melanoma Research · 2013 · 31 citations

, , +17

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

Hildur Helgadóttir, Lars Ny, Gustav Ullenhag et al. · JNCI Journal of the National Cancer Institute · 2023 · 27 citations · Full text

, , +17

Surgical treatment of skeletal metastases in 31 melanoma patients.

Rikard Wedin, Johan Falkenius, Rüdiger J Weiss et al. · PubMed · 2012 · 20 citations

, , +17

A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: Dose-escalation results.

Baukelien van Triest, Lars Damstrup, Johan Falkenius et al. · Journal of Clinical Oncology · 2018 · 19 citations

, , +17

1–5 of 7